{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T20:05:57Z","timestamp":1770753957739,"version":"3.50.0"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,6,7]],"date-time":"2020-06-07T00:00:00Z","timestamp":1591488000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,7]],"date-time":"2020-06-07T00:00:00Z","timestamp":1591488000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100010621","name":"Uniwersytet Medyczny w Lublinie","doi-asserted-by":"publisher","award":["DS 474\/2015-2017"],"award-info":[{"award-number":["DS 474\/2015-2017"]}],"id":[{"id":"10.13039\/501100010621","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacol. Rep"],"published-print":{"date-parts":[[2020,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Launching polytherapy with two or three antiseizure drugs (ASDs) in patients with epilepsy is still problematic. The choice of ASDs to combine them together is usually based on clinicians\u2019 experience and it requires knowledge about mechanisms of action of the studied ASDs and their drug\u2013drug interactions, whose nature may be favorable, neutral or unfavorable. To characterize three-drug interaction among lacosamide (LCM), lamotrigine (LTG) and valproate (VPA), the type I isobolographic analysis was used. The antiseizure effects of three-drug combination were analyzed in a model of maximal electroshock-induced seizures (MES) in albino Swiss mice.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Materials and methods<\/jats:title>\n<jats:p>The seizure activity in mice was evoked by alternating current stimulation (25\u00a0mA, 500\u00a0V, 50\u00a0Hz, 0.2\u00a0s). Both, the type I isobolographic analysis and the test of parallelism of dose-response effects of the ASDs were used so as to properly classify interaction among three ASDs, administered in a fixed ratio combination of 1:1:1.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>The three-drug mixture of LCM, LTG and VPA at the fixed ratio of 1:1:1 protected the experimental mice from MES-induced seizures; however, the reported interaction was sub-additive (antagonistic; <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.01) with isobolography.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>The antagonistic pharmacodynamic interaction among LCM, LTG and VPA in the MES test in mice cannot be transferred to clinical settings and this unfavorable combination should not be recommended for patients with epilepsy.<\/jats:p>\n<\/jats:sec>","DOI":"10.1007\/s43440-020-00117-y","type":"journal-article","created":{"date-parts":[[2020,6,7]],"date-time":"2020-06-07T09:02:36Z","timestamp":1591520556000},"page":"1288-1296","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Sub-additive (antagonistic) interaction of lacosamide with lamotrigine and valproate in the maximal electroshock-induced seizure model in mice: an isobolographic analysis"],"prefix":"10.1007","volume":"72","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3059-0393","authenticated-orcid":false,"given":"Jarogniew J.","family":"\u0141uszczki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6614-8807","authenticated-orcid":false,"given":"Maria","family":"Kondrat-Wr\u00f3bel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0079-0490","authenticated-orcid":false,"given":"Miros\u0142aw","family":"Zagaja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S\u0142awomir","family":"Karwan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4887-7541","authenticated-orcid":false,"given":"Hubert","family":"Bojar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6255-5085","authenticated-orcid":false,"given":"Zbigniew","family":"Plewa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1489-2399","authenticated-orcid":false,"given":"Magdalena","family":"Florek-\u0141uszczki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,6,7]]},"reference":[{"key":"117_CR1","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.seizure.2011.01.004","volume":"20","author":"MJ Brodie","year":"2011","unstructured":"Brodie MJ, Sills GJ. Combining antiepileptic drugs\u2013rational polytherapy? Seizure. 2011;20:369\u201375.","journal-title":"Seizure"},{"key":"117_CR2","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.2165\/00003495-200666140-00004","volume":"66","author":"P Kwan","year":"2006","unstructured":"Kwan P, Brodie MJ. Combination therapy in epilepsy: when and what to use. Drugs. 2006;66:1817\u201329.","journal-title":"Drugs"},{"key":"117_CR3","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.eplepsyres.2017.02.020","volume":"132","author":"J Makinen","year":"2017","unstructured":"Makinen J, Rainesalo S, Raitanen J, Peltola J. The effect of newer antiepileptic drugs in combination therapy. Epilepsy Res. 2017;132:15\u201320.","journal-title":"Epilepsy Res"},{"key":"117_CR4","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.eplepsyres.2011.09.008","volume":"98","author":"LJ Stephen","year":"2012","unstructured":"Stephen LJ, Forsyth M, Kelly K, Brodie MJ. Antiepileptic drug combinations\u2013have newer agents altered clinical outcomes? Epilepsy Res. 2012;98:194\u20138.","journal-title":"Epilepsy Res"},{"key":"117_CR5","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/0140-6736(93)93048-6","volume":"341","author":"CP Panayiotopoulos","year":"1993","unstructured":"Panayiotopoulos CP, Ferrie CD, Knott C, Robinson RO. Interaction of lamotrigine with sodium valproate. Lancet. 1993;341:445.","journal-title":"Lancet"},{"key":"117_CR6","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/0140-6736(93)91062-Q","volume":"341","author":"F Pisani","year":"1993","unstructured":"Pisani F, Di Perri R, Perucca E, Richens A. Interaction of lamotrigine with sodium valproate. Lancet. 1993;341:1224.","journal-title":"Lancet"},{"key":"117_CR7","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.yebeh.2014.05.031","volume":"37","author":"KD Laxer","year":"2014","unstructured":"Laxer KD, Trinka E, Hirsch LJ, Cendes F, Langfitt J, Delanty N, et al. The consequences of refractory epilepsy and its treatment. Epilepsy Behav. 2014;37:59\u201370.","journal-title":"Epilepsy Behav"},{"key":"117_CR8","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.phrs.2016.03.016","volume":"107","author":"L Santulli","year":"2016","unstructured":"Santulli L, Coppola A, Balestrini S, Striano S. The challenges of treating epilepsy with 25 antiepileptic drugs. Pharmacol Res. 2016;107:211\u20139.","journal-title":"Pharmacol Res"},{"key":"117_CR9","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.eplepsyres.2017.10.004","volume":"143","author":"J Slater","year":"2018","unstructured":"Slater J, Chung S, Huynh L, Duh MS, Gorin B, McMicken C, et al. Efficacy of antiepileptic drugs in the adjunctive treatment of refractory partial-onset seizures: Meta-analysis of pivotal trials. Epilepsy Res. 2018;143:120\u20139.","journal-title":"Epilepsy Res"},{"key":"117_CR10","first-page":"279","volume":"150","author":"F De Romanis","year":"1999","unstructured":"De Romanis F, Sopranzi N. [Lamotrigine in the therapy of resistant epilepsy] in Italian. Clin Terapeut. 1999;150:279\u201382.","journal-title":"Clin Terapeut"},{"key":"117_CR11","first-page":"153","volume":"148","author":"F De Romanis","year":"1997","unstructured":"De Romanis F, Sopranzi N. [Lamotrigine: monotherapy in refractory epilepsy] in Italian. Clin Terapeut. 1997;148:153\u20138.","journal-title":"Clin Terapeut"},{"key":"117_CR12","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.eplepsyres.2003.08.003","volume":"56","author":"JJ Luszczki","year":"2003","unstructured":"Luszczki JJ, Czuczwar SJ. Isobolographic and subthreshold methods in the detection of interactions between oxcarbazepine and conventional antiepileptics: a comparative study. Epilepsy Res. 2003;56:27\u2013422.","journal-title":"Epilepsy Res"},{"key":"117_CR13","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1111\/j.0013-9580.2004.05104.x","volume":"45","author":"JJ Luszczki","year":"2004","unstructured":"Luszczki JJ, Czuczwar SJ. Preclinical profile of combinations of some second-generation antiepileptic drugs: an isobolographic analysis. Epilepsia. 2004;45:895\u2013907.","journal-title":"Epilepsia"},{"key":"117_CR14","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s00210-007-0144-z","volume":"375","author":"JJ Luszczki","year":"2007","unstructured":"Luszczki JJ. Isobolographic analysis of interaction between drugs with nonparallel dose-response relationship curves: a practical application. Naunyn Schmiedebergs Arch Pharmacol. 2007;375:105\u201314.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"117_CR15","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.ejphar.2014.08.001","volume":"741","author":"N Matsumura","year":"2014","unstructured":"Matsumura N, Nakaki T. Isobolographic analysis of the mechanisms of action of anticonvulsants from a combination effect. Eur J Pharmacol. 2014;741:237\u201346.","journal-title":"Eur J Pharmacol"},{"key":"117_CR16","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1111\/j.1528-1157.2000.tb00111.x","volume":"41","author":"CL Deckers","year":"2000","unstructured":"Deckers CL, Czuczwar SJ, Hekster YA, Keyser A, Kubova H, Meinardi H, et al. Selection of antiepileptic drug polytherapy based on mechanisms of action: the evidence reviewed. Epilepsia. 2000;41:1364\u201374.","journal-title":"Epilepsia"},{"key":"117_CR17","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1097\/WCO.0b013e328350ba68","volume":"25","author":"LJ Stephen","year":"2012","unstructured":"Stephen LJ, Brodie MJ. Antiepileptic drug monotherapy versus polytherapy: pursuing seizure freedom and tolerability in adults. Curr Opin Neurol. 2012;25:164\u201372.","journal-title":"Curr Opin Neurol"},{"key":"117_CR18","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1053\/seiz.2002.0711","volume":"11","author":"LJ Stephen","year":"2002","unstructured":"Stephen LJ, Brodie MJ. Seizure freedom with more than one antiepileptic drug. Seizure. 2002;11:349\u201351.","journal-title":"Seizure"},{"key":"117_CR19","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1046\/j.1528-1157.2003.10003.x","volume":"44","author":"JJ Luszczki","year":"2003","unstructured":"Luszczki JJ, Czuczwar M, Kis J, Krysa J, Pasztelan I, Swiader M, et al. Interactions of lamotrigine with topiramate and first-generation antiepileptic drugs in the maximal electroshock test in mice: an isobolographic analysis. Epilepsia. 2003;44:1003\u201313.","journal-title":"Epilepsia"},{"key":"117_CR20","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0140-6736(05)60613-7","volume":"351","author":"LJ Stephen","year":"1998","unstructured":"Stephen LJ, Sills GJ, Brodie MJ. Lamotrigine and topiramate may be a useful combination. Lancet. 1998;351:958\u20139.","journal-title":"Lancet"},{"key":"117_CR21","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.seizure.2007.08.001","volume":"17","author":"J Peltola","year":"2008","unstructured":"Peltola J, Peltola M, Raitanen J, Keranen T, Kharazmi E, Auvinen A. Seizure-freedom with combination therapy in localization-related epilepsy. Seizure. 2008;17:276\u201380.","journal-title":"Seizure"},{"key":"117_CR22","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1046\/j.1528-1157.2002.34301.x","volume":"43","author":"KK Borowicz","year":"2002","unstructured":"Borowicz KK, Swiader M, Luszczki J, Czuczwar SJ. Effect of gabapentin on the anticonvulsant activity of antiepileptic drugs against electroconvulsions in mice: an isobolographic analysis. Epilepsia. 2002;43:956\u201363.","journal-title":"Epilepsia"},{"key":"117_CR23","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/j.1528-1167.2006.00364.x","volume":"47","author":"JJ Luszczki","year":"2006","unstructured":"Luszczki JJ, Andres MM, Czuczwar P, Cioczek-Czuczwar A, Ratnaraj N, Patsalos PN, et al. Pharmacodynamic and pharmacokinetic characterization of interactions between levetiracetam and numerous antiepileptic drugs in the mouse maximal electroshock seizure model: an isobolographic analysis. Epilepsia. 2006;47:10\u201320.","journal-title":"Epilepsia"},{"key":"117_CR24","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1111\/j.1528-1167.2009.02397.x","volume":"51","author":"P Kwan","year":"2010","unstructured":"Kwan P, Arzimanoglou A, Berg AT, Brodie MJ, Allen Hauser W, Mathern G, et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia. 2010;51:1069\u201377.","journal-title":"Epilepsia"},{"key":"117_CR25","doi-asserted-by":"crossref","first-page":"14","DOI":"10.14581\/jer.19002","volume":"9","author":"KM Park","year":"2019","unstructured":"Park KM, Kim SE, Lee BI. Antiepileptic drug therapy in patients with drug-resistant epilepsy. J Epilepsy Res. 2019;9:14\u201326.","journal-title":"J Epilepsy Res"},{"key":"117_CR26","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s11910-016-0678-x","volume":"16","author":"MJ Brodie","year":"2016","unstructured":"Brodie MJ. Pharmacological treatment of drug-resistant epilepsy in adults: a practical guide. Curr Neurol Neurosci Rep. 2016;16:82.","journal-title":"Curr Neurol Neurosci Rep"},{"key":"117_CR27","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.seizure.2016.08.010","volume":"44","author":"MJ Brodie","year":"2017","unstructured":"Brodie MJ. Outcomes in newly diagnosed epilepsy in adolescents and adults: insights across a generation in Scotland. Seizure. 2017;44:206\u201310.","journal-title":"Seizure"},{"key":"117_CR28","doi-asserted-by":"publisher","first-page":"107790","DOI":"10.1016\/j.neuropharm.2019.107790","volume":"168","author":"M Janmohamed","year":"2020","unstructured":"Janmohamed M, Brodie MJ, Kwan P. Pharmacoresistance - epidemiology, mechanisms, and impact on epilepsy treatment. Neuropharmacology. 2020;168:107790. https:\/\/doi.org\/10.1016\/j.neuropharm.2019.107790.","journal-title":"Neuropharmacology"},{"key":"117_CR29","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.yebeh.2015.09.006","volume":"52","author":"V Biton","year":"2015","unstructured":"Biton V, Gil-Nagel A, Isojarvi J, Doty P, Hebert D, Fountain NB. Safety and tolerability of lacosamide as adjunctive therapy for adults with partial-onset seizures: Analysis of data pooled from three randomized, double-blind, placebo-controlled clinical trials. Epilepsy Behav. 2015;52:119\u201327.","journal-title":"Epilepsy Behav"},{"key":"117_CR30","doi-asserted-by":"crossref","unstructured":"Weston J, Shukralla A, McKay AJ, Marson AG. Lacosamide add-on therapy for partial epilepsy. Cochrane Database Sys Rev. 2015;6:Cd008841. doi: 10.1002\/14651858.CD008841.pub2","DOI":"10.1002\/14651858.CD008841.pub2"},{"key":"117_CR31","doi-asserted-by":"crossref","first-page":"55","DOI":"10.5114\/hpc.2016.58209","volume":"10","author":"MW Kondrat-Wrobel","year":"2016","unstructured":"Kondrat-Wrobel MW, Luszczki JJ. Interaction of three-drug combination of lacosamide, carbamazepine and phenobarbital in the mouse maximal electroshock-induced seizure model: an isobolographic analysis. Health Probl Civil. 2016;10:55\u201361.","journal-title":"Health Probl Civil"},{"key":"117_CR32","doi-asserted-by":"crossref","first-page":"54","DOI":"10.5114\/hpc.2016.63572","volume":"10","author":"D Zolkowska","year":"2016","unstructured":"Zolkowska D, Zagaja M, Miziak B, Kondrat-Wrobel MW, Zaluska K, Florek-Luszczki M, et al. Isobolographic assessment of interactions between retigabine and phenytoin in the mouse maximal electroshock-induced seizure model and chimney test. Health Prob Civil. 2016;10:54\u20139.","journal-title":"Health Prob Civil"},{"key":"117_CR33","doi-asserted-by":"crossref","unstructured":"Loscher W, Fassbender CP, Nolting B. The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. II. Maximal electroshock seizure models. Epilepsy Res. 1991;8:79\u201394.","DOI":"10.1016\/0920-1211(91)90075-Q"},{"key":"117_CR34","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1111\/j.1476-5381.2010.00872.x","volume":"160","author":"C Kilkenny","year":"2010","unstructured":"Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG. Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol. 2010;160:1577\u20139.","journal-title":"Br J Pharmacol"},{"key":"117_CR35","doi-asserted-by":"crossref","first-page":"881","DOI":"10.17219\/acem\/69132","volume":"27","author":"MW Kondrat-Wrobel","year":"2018","unstructured":"Kondrat-Wrobel MW, Luszczki JJ. Isobolographic additivity among lacosamide, lamotrigine and phenobarbital in the mouse tonic-clonic seizure model. Adv Clin Exp Med. 2018;27:881\u20136.","journal-title":"Adv Clin Exp Med"},{"key":"117_CR36","doi-asserted-by":"crossref","first-page":"303","DOI":"10.15584\/ejcem.2017.4.1","volume":"15","author":"MW Kondrat-Wr\u00f3bel","year":"2017","unstructured":"Kondrat-Wr\u00f3bel MW, Luszczki JJ. Additive interaction for three-drug combination of carbamazepine, lacosamide and lamotrigine against maximal electroshock-induced seizures \u2013 a type I isobolographic analysis. Eur J Clin Exp Med. 2017;15:303\u20139.","journal-title":"Eur J Clin Exp Med"},{"key":"117_CR37","doi-asserted-by":"crossref","first-page":"92","DOI":"10.5114\/hpc.2019.81105","volume":"13","author":"MW Kondrat-Wr\u00f3bel","year":"2019","unstructured":"Kondrat-Wr\u00f3bel MW, Za\u0142uska K, Walczak A, Panasiuk-Poterek AN, Gut-Lepiech A, Wr\u00f3blewska-\u0141uczka P, et al. Antagonistic interaction of lacosamide with carbamazepine and valproate in the mouse tonic-clonic seizure model. Health Prob Civil. 2019;13:92\u20138.","journal-title":"Health Prob Civil"},{"key":"117_CR38","doi-asserted-by":"crossref","first-page":"111","DOI":"10.26444\/jpccr\/101578","volume":"12","author":"K Za\u0142uska","year":"2018","unstructured":"Za\u0142uska K, Kondrat-Wr\u00f3bel MW, Panasiuk-Poterek AN, Marz\u0119da P, Walczak A, Wr\u00f3blewska-\u0141uczka P, et al. Synergy among oxcarbazepine, pregabalin and topiramate in the mouse maximal electroshockinduced seizure test: an isobolographic analysis. J Pre-Clin Clin Res. 2018;12:111\u20136.","journal-title":"J Pre-Clin Clin Res"},{"key":"117_CR39","doi-asserted-by":"crossref","first-page":"72","DOI":"10.26444\/jpccr\/109381","volume":"13","author":"K Za\u0142uska","year":"2019","unstructured":"Za\u0142uska K, Marz\u0119da P, Bojar H, Walczak A, Chmielewski J, Wr\u00f3blewska-\u0141uczka P, et al. Additive suppression of tonic-clonic seizures in mice receiving the combination of carbamazepine, phenobarbital and valproate. J Pre-Clin Clin Res. 2019;13:72\u20135.","journal-title":"J Pre-Clin Clin Res"},{"key":"117_CR40","first-page":"99","volume":"96","author":"JT Litchfield Jr","year":"1949","unstructured":"Litchfield JT Jr, Wilcoxon F. A simplified method of evaluating dose-effect experiments. J Pharmacol Exp Ther. 1949;96:99\u2013113.","journal-title":"J Pharmacol Exp Ther"},{"key":"117_CR41","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1159\/000444452","volume":"97","author":"JJ Luszczki","year":"2016","unstructured":"Luszczki JJ. Isobolographic analysis of interaction for three-drug combination of carbamazepine, phenobarbital and topiramate in the mouse maximal electroshock-induced seizure model. Pharmacology. 2016;97:259\u201364.","journal-title":"Pharmacology"},{"key":"117_CR42","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s00210-006-0100-3","volume":"374","author":"JJ Luszczki","year":"2006","unstructured":"Luszczki JJ, Czuczwar SJ. Biphasic characteristic of interactions between stiripentol and carbamazepine in the mouse maximal electroshock-induced seizure model: a three-dimensional isobolographic analysis. Naunyn Schmiedebergs Arch Pharmacol. 2006;374:51\u201364.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"117_CR43","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.eplepsyres.2018.06.003","volume":"145","author":"JJ Luszczki","year":"2018","unstructured":"Luszczki JJ, Mazurkiewicz LP, Wroblewska-Luczka P, Wlaz A, Ossowska G, Szpringer M, et al. Combination of phenobarbital with phenytoin and pregabalin produces synergy in the mouse tonic-clonic seizure model: an isobolographic analysis. Epilepsy Res. 2018;145:116\u201322.","journal-title":"Epilepsy Res"},{"key":"117_CR44","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1124\/jpet.112.193474","volume":"342","author":"RJ Tallarida","year":"2012","unstructured":"Tallarida RJ. Revisiting the isobole and related quantitative methods for assessing drug synergism. J Pharmacol Exp Ther. 2012;342:2\u20138. https:\/\/doi.org\/10.1124\/jpet.112.193474.","journal-title":"J Pharmacol Exp Ther"},{"key":"117_CR45","doi-asserted-by":"crossref","unstructured":"Tallarida RJ. Drug combinations: tests and analysis with isoboles. Curr Protocol Pharmacol. 2016;72:9.19.1\u20139.19.19. doi:10.1002\/0471141755.ph0919s72","DOI":"10.1002\/0471141755.ph0919s72"},{"key":"117_CR46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1124\/jpet.106.104117","volume":"319","author":"RJ Tallarida","year":"2006","unstructured":"Tallarida RJ. An overview of drug combination analysis with isobolograms. J Pharmacol Exp Ther. 2006;319:1\u20137.","journal-title":"J Pharmacol Exp Ther"},{"key":"117_CR47","first-page":"31","volume":"162","author":"E Perucca","year":"1995","unstructured":"Perucca E. Pharmacological principles as a basis for polytherapy. Acta Neurol Scand Suppl. 1995;162:31\u20134.","journal-title":"Acta Neurol Scand Suppl"},{"key":"117_CR48","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.phrs.2015.11.007","volume":"103","author":"V Franco","year":"2016","unstructured":"Franco V, French JA, Perucca E. Challenges in the clinical development of new antiepileptic drugs. Pharmacol Res. 2016;103:95\u2013104.","journal-title":"Pharmacol Res"},{"issue":"Suppl 4","key":"117_CR49","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/epi.12294","volume":"54","author":"JA French","year":"2013","unstructured":"French JA, White HS, Klitgaard H, Holmes GL, Privitera MD, Cole AJ, et al. Development of new treatment approaches for epilepsy: unmet needs and opportunities. Epilepsia. 2013;54(Suppl 4):3\u201312.","journal-title":"Epilepsia"},{"key":"117_CR50","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0920-1211(02)00182-1","volume":"52","author":"E Perucca","year":"2002","unstructured":"Perucca E. Overtreatment in epilepsy: adverse consequences and mechanisms. Epilepsy Res. 2002;52:25\u201333.","journal-title":"Epilepsy Res"},{"key":"117_CR51","doi-asserted-by":"crossref","first-page":"897","DOI":"10.2165\/00023210-200519110-00001","volume":"19","author":"E Perucca","year":"2005","unstructured":"Perucca E, Kwan P. Overtreatment in epilepsy: how it occurs and how it can be avoided. CNS Drugs. 2005;19:897\u2013908.","journal-title":"CNS Drugs"},{"key":"117_CR52","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.yebeh.2015.02.010","volume":"45","author":"PH McCabe","year":"2015","unstructured":"McCabe PH. Would Sherlock Holmes agree with our definition of rational polytherapy? A proposal for a national data bank on patients with epilepsy. Epilepsy Behav. 2015;45:147\u201350.","journal-title":"Epilepsy Behav"},{"key":"117_CR53","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.2147\/NDT.S84852","volume":"12","author":"L Dalic","year":"2016","unstructured":"Dalic L, Cook MJ. Managing drug-resistant epilepsy: challenges and solutions. Neuropsych Dis Treat. 2016;12:2605\u201316.","journal-title":"Neuropsych Dis Treat"},{"key":"117_CR54","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1097\/00002826-198808000-00003","volume":"11","author":"BF Bourgeois","year":"1988","unstructured":"Bourgeois BF. Anticonvulsant potency and neurotoxicity of valproate alone and in combination with carbamazepine or phenobarbital. Clin Neuropharmacol. 1988;11:348\u201359.","journal-title":"Clin Neuropharmacol"},{"key":"117_CR55","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1007\/s11064-015-1749-0","volume":"41","author":"M Sitges","year":"2016","unstructured":"Sitges M, Chiu LM, Reed RC. Effects of levetiracetam, carbamazepine, phenytoin, valproate, lamotrigine, oxcarbazepine, topiramate, vinpocetine and sertraline on presynaptic hippocampal Na(+) and Ca(2+) channels permeability. Neurochem Res. 2016;41:758\u201369.","journal-title":"Neurochem Res"},{"key":"117_CR56","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.pharep.2013.10.005","volume":"66","author":"MJ Swiader","year":"2014","unstructured":"Swiader MJ, Kotowski J, Luszczki JJ. Modulation of adenosinergic system and its application for the treatment of epilepsy. Pharmacol Rep. 2014;66:335\u201342.","journal-title":"Pharmacol Rep"},{"key":"117_CR57","first-page":"285","volume":"3","author":"S Loewe","year":"1953","unstructured":"Loewe S. The problem of synergism and antagonism of combined drugs. Arzneimittelforschung. 1953;3:285\u201390.","journal-title":"Arzneimittelforschung"},{"key":"117_CR58","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1177\/0091270011426875","volume":"52","author":"W Cawello","year":"2012","unstructured":"Cawello W, Bonn R. No pharmacokinetic interaction between lacosamide and valproic acid in healthy volunteers. J Clin Pharmacol. 2012;52:1739\u201348.","journal-title":"J Clin Pharmacol"},{"key":"117_CR59","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1007\/s40262-015-0276-0","volume":"54","author":"W Cawello","year":"2015","unstructured":"Cawello W. Clinical pharmacokinetic and pharmacodynamic profile of lacosamide. Clin Pharmacokin. 2015;54:901\u201314.","journal-title":"Clin Pharmacokin"},{"key":"117_CR60","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1111\/epi.12237","volume":"54","author":"A Shandra","year":"2013","unstructured":"Shandra A, Shandra P, Kaschenko O, Matagne A, Stohr T. Synergism of lacosamide with established antiepileptic drugs in the 6-Hz seizure model in mice. Epilepsia. 2013;54:1167\u201375.","journal-title":"Epilepsia"},{"key":"117_CR61","first-page":"1","volume":"28","author":"MC Berenbaum","year":"1977","unstructured":"Berenbaum MC. Synergy, additivism and antagonism in immunosuppression: a critical review. Clin Exp Immunol. 1977;28:1\u201318.","journal-title":"Clin Exp Immunol"}],"container-title":["Pharmacological Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-020-00117-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43440-020-00117-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-020-00117-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,6]],"date-time":"2021-06-06T23:20:30Z","timestamp":1623021630000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s43440-020-00117-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,7]]},"references-count":61,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["117"],"URL":"https:\/\/doi.org\/10.1007\/s43440-020-00117-y","relation":{},"ISSN":["1734-1140","2299-5684"],"issn-type":[{"value":"1734-1140","type":"print"},{"value":"2299-5684","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,7]]},"assertion":[{"value":"29 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors have no conflict of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}